H.C. Wainwright raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $110 from $100 and keeps a Buy rating on the shares. The firm believes Olezarsen is positioned to become the new standard for severe hypertriglyceridemia.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Promising Potential of Ionis Pharmaceuticals’ Olezarsen Drives Buy Rating
- Ionis Pharmaceuticals announces Phase 3 CORE, CORE2 met primary endpoint
- Cathie Wood Buys the Dip in Archer Aviation (ACHR) After Weak Q3 Results, Trims Stakes in Roku and TER Stocks
- Ionis Pharmaceuticals presents data on Dawnzera at ACAAI 2025 Annual Meeting
- Ionis Pharmaceuticals price target raised to $77 from $70 at Piper Sandler